Drug Type T cell engagers (TCE) |
Synonyms FPE 021, FPE021 |
Target |
Action inhibitors, stimulants, antagonists |
Mechanism CD28 inhibitors(T-cell-specific surface glycoprotein CD28 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CDH17 antagonists(Cadherin-17 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | China | 15 Jun 2024 |